Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 6-(nitrooxy)-hexanoic acid, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Kowa Company
Deal Size : $231.2 million
Deal Type : Agreement
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for NCX 470
Details : Kowa gets exclusive rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop.
Product Name : NCX 470
Product Type : HPAPI
Upfront Cash : $8.7 million
July 17, 2025
Lead Product(s) : 6-(nitrooxy)-hexanoic acid, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Kowa Company
Deal Size : $231.2 million
Deal Type : Agreement
Reset All
